Clinical trial · Observational
The Correlation Between Circulatory Tumor Cells and Venous Thrombosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Research indicates a strong correlation between cancer and thrombosis, with approximately 20% of blood clots in the U.S. being cancer-related, according to CDC data. Cancer patients face a 4-7 times higher risk of thrombosis compared to non-cancer individuals. Certain cancer treatments, such as chemotherapy and targeted therapy, elevate the likelihood of venous thromboembolism (VTE). Cancer patients with VTE exhibit a significantly higher hazard ratio (H.R.) of 3.4 compared to those without VTE. This study aims to explore three main topics: (1) Comparing the differences and similarities of leukocyte populations between cancer-associated thrombosis (CAT) and venous thromboembolism (VTE). (2) Characterizing the factors contributing to increased incidence of cancer-associated thrombosis (CAT), with the hypothesis that circulating tumor microemboli (CTM) may express more thrombosis-related proteins than CTCs. (3) Understanding the effects of aspirin or NOACs on cancer-associated thrombosis and CTM formation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumor Cells, Circulating | — | UNRESOLVED | — |
| Venous Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CTCs/CTMs culture | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- cancer for CTC culture
- description
- a thrombosis patient with cancer .
- interventionNames
- Procedure: CTCs/CTMs culture
- label
- health for CTC culture
- description
- a thrombosis patient without cancer
- interventionNames
- Procedure: CTCs/CTMs culture
Primary outcomes (2)
- measure
- cell culture
- timeFrame
- baseline
- description
- cancer-specific surface markers
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. age≧18 2. participants (1)participants without cancer: without cancer in five years (2)participants with cancer:pathology reveal have malignant tumor 3. patients who underwent catheter-based thrombectomy 4. agree do the thrombectomy Exclusion Criteria: 1. participants without cancer (1).shock (2).severe sepsis (3).with cancer in five years 2. participants with cancer (1).shock (2).severe sepsis
References
Publications (1)
- RESULTFalanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie. 2012;32(2):115-25. doi: 10.5482/ha-1170. Epub 2011 Oct 5. PMID 21971578